查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085265

大腸直腸癌治療市場：依藥物類別、給藥途徑、治療階段、標靶分子、治療環境和通路分類－全球預測，2026-2032年

Colorectal Cancer Drugs Market by Drug Class, Route Of Administration, Line Of Therapy, Target Molecule, Treatment Setting, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，大腸直腸癌治療市場將成長至 195.7 億美元，複合年成長率為 7.24%。

主要市場統計數據
基準年 2025 119.9億美元
預計年份：2026年 126.6億美元
預測年份 2032 195.7億美元
複合年成長率 (%) 7.24%

大腸直腸癌治療市場概覽

大腸直腸癌的治療正從以廣泛化療為主轉向基於生物標記、免疫腫瘤學和針對腫瘤生物學特徵的標靶治療的聯合療法。大腸直腸癌仍然是全球最嚴重的癌症之一。根據世界衛生組織（WHO）發布的《2022年全球癌症風險評估報告》（GLOBOCAN 2022），預計全球整體將新增超過190萬例結直腸癌病例，死亡人數超過90萬，使其成為第三大癌症診斷原因和第二大癌症死亡原因。

大腸直腸癌治療前景的變革性變化

精準醫療、早期生物標記檢測和聯合治療的日益普及正在改變大腸直腸癌的治療模式。各大腫瘤學會指引越來越建議對轉移性大腸直腸癌進行全面的分子譜分析，從而將處方策略從序貫使用單一細胞毒性藥物轉變為根據訊號路徑制定個人化治療方案。

人工智慧對大腸直腸癌治療藥物的累積影響

人工智慧（AI）正對大腸直腸癌治療的各個領域產生累積影響，從藥物發現和臨床開發到診斷和商業化。在藥物發現階段，AI驅動的建模能夠實現標靶優先排序、類藥分子識別和抗藥性通路分析，從而加速從基因組學、轉錄組學、病理圖像和真實世界臨床資料集中產生假設。

全球大腸直腸癌治療市場的關鍵區域洞察

北美憑藉其強大的腫瘤學研究基礎設施、高分子診斷普及率、廣泛的生物製藥和免疫療法獲取途徑以及成熟的醫保報銷體系，主導。美國主導該地區的大部分臨床試驗活動和藥物上市計劃，而加拿大則繼續透過衛生技術評估和省級醫保報銷流程，優先考慮循證醫學的可及性。

針對特定族群的結直腸癌治療商業策略的關鍵見解

七國集團（G7）憑藉著大規模的腫瘤治療預算、先進的臨床試驗網路以及標靶治療的高普及率，在結直腸癌治療的創新、醫保報銷政策和臨床指南制定方面繼續發揮核心作用。歐盟正透過協調監管流程和進行跨境研究舉措來擴大市場規模，但治療的可及性仍取決於各國的衛生技術評估、預算影響評估以及價格談判。

深入了解影響大腸直腸癌治療需求的關鍵國家

美國在結直腸癌治療藥物的研發和推廣方面具有舉足輕重的地位，這得益於FDA的創新核准途徑、廣泛的腫瘤臨床試驗活動以及基於生物標記的療法的快速普及。然而，支付方對高價療法的審查也日益嚴格。加拿大強調臨床價值和公共保險報銷的合理性，而墨西哥的進展則依賴於加強篩檢、提高診斷可及性以及完善腫瘤專科醫療體系。巴西是拉丁美洲的主要市場，其需求受到公立和私立醫療體系差異以及生物相似藥和標靶治療可及性的影響。

為大腸直腸癌製藥行業的領導者提供的實用建議

產業領導者應優先考慮以生物標記主導的研發策略，使候選藥物與檢驗的診斷路徑和明確定義的患者群體相符。基於MSI-H/dMMR、BRAF突變、HER2陽性、KRAS突變和其他分子標靶選擇的結直腸癌患者群體，不斷累積的證據有助於建構差異化市場定位，並為醫保報銷提供更有力的依據。

基於證據的市場資訊調查方法

本執行摘要採用系統的二手調查方法編寫，重點關注經檢驗的公共領域和行業認可的資訊來源。輸入資料包括來自世界衛生組織和國際癌症研究機構/全球癌症負擔研究組（IARC/GLOBOCAN）的全球癌症負擔資料、來自美國食品藥物管理局（FDA）、歐洲藥品管理局（EMA）和各國主管機構的監管資訊、腫瘤學會的臨床指南、同行評審文獻、衛生技術評估（HTA）結果以及公共衛生資源。

結論：大腸直腸癌治療的策略展望

大腸直腸癌治療領域正朝著更精準、數據驅動的方向發展，分子檢測、免疫療法、標靶治療以及真實世界數據在決定臨床和商業性成功方面正發揮著日益重要的作用。儘管化療仍然是基礎治療手段，但最大的機會正湧現於生物標記定義的特定患者群體以及那些在生存率、耐受性和可及性方面展現出顯著優勢的療法中。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：大腸直腸癌治療市場：依藥物類別分類

  • 化療
    • Fluoropyrimidines藥物
    • 含鉑類藥物
    • 拓樸異構酶抑制劑
  • 免疫療法
    • 過繼性細胞療法
    • 查核點抑制劑
  • 單株抗體
    • 表皮生長因子受體抑制劑
    • 血管內皮生長因子抑制劑
  • 小分子抑制劑
    • BRAF抑制劑
    • MEK抑制劑
    • 蛋白酪氨酸激酶抑制劑

第8章：大腸直腸癌治療市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第9章：大腸直腸癌治療市場：依治療階段分類

  • 第 1 行
  • 第二行
  • 第三行

第10章：大腸直腸癌治療市場：以標靶分子分類

  • 表皮生長因子受體
  • 程序性細胞死亡蛋白1
  • 程序性死亡配體1
  • 血管內皮生長因子

第11章：大腸直腸癌治療市場：依治療環境分類

  • 住院治療
  • 門診

第12章：大腸直腸癌治療藥物市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：大腸直腸癌治療藥物市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：大腸直腸癌治療藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：大腸直腸癌治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Accord Healthcare Limited by Intas Pharmaceuticals Ltd.
  • Amgen Inc.
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • HUTCHMED（China）Limited
  • Johnson & Johnson
  • Lupin Limited
  • Mallinckrodt Pharmaceuticals
  • Manus Aktteva Biopharma LLP
  • Marksans Pharma Ltd.
  • Merck & Co., Inc.
  • Mylan NV by Viatris Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Servier Laboratories
  • Sumitomo Pharma Co., Ltd.
  • Taiho Pharmaceutical Co., Ltd. by Otsuka Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • VolitionRx Limited
Product Code: MRR-431B7BFFBF56

The Colorectal Cancer Drugs Market is projected to grow by USD 19.57 billion at a CAGR of 7.24% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.99 billion
Estimated Year [2026] USD 12.66 billion
Forecast Year [2032] USD 19.57 billion
CAGR (%) 7.24%

Colorectal Cancer Drugs Executive Overview

Colorectal cancer drugs are moving from broad chemotherapy backbones toward biomarker-directed, immuno-oncology, and targeted combinations that align treatment with tumor biology. Colorectal cancer remains one of the most burdensome cancers worldwide; the World Health Organization's GLOBOCAN 2022 estimates more than 1.9 million new colorectal cancer cases and over 900,000 deaths globally, making it the third most commonly diagnosed cancer and the second leading cause of cancer death.

Demand for colorectal cancer therapeutics is supported by rising screening uptake in developed markets, increasing early-onset colorectal cancer incidence reported in multiple epidemiology studies, and wider use of molecular testing for KRAS, NRAS, BRAF, MSI-H/dMMR, HER2, NTRK, and other actionable markers. Standard treatment still includes fluoropyrimidines, oxaliplatin, irinotecan, VEGF inhibitors, and EGFR inhibitors, while newer agents such as immune checkpoint inhibitors, BRAF-targeted combinations, HER2-directed therapies, and antibody-drug conjugate pipelines are reshaping competitive positioning.

For industry leaders, the opportunity lies in therapies that improve survival, reduce toxicity, expand access across care settings, and demonstrate value under increasingly evidence-driven reimbursement models.

Transformative Shifts in the Colorectal Cancer Therapeutics Landscape

The colorectal cancer drugs landscape is being transformed by precision medicine, earlier biomarker testing, and the growing role of combination regimens. Guidelines from major oncology societies increasingly support comprehensive molecular profiling in metastatic colorectal cancer, which has shifted prescribing from one-size-fits-all cytotoxic sequencing to pathway-specific treatment decisions.

Immunotherapy has created a clear therapeutic divide between MSI-H/dMMR tumors and microsatellite-stable disease. Checkpoint inhibitors have become a standard option for eligible MSI-H/dMMR metastatic colorectal cancer, while most patients with microsatellite-stable tumors still require chemotherapy, anti-VEGF, anti-EGFR, or investigational combination approaches. This has intensified research into tumor microenvironment modulation, bispecific antibodies, cancer vaccines, cell therapies, and rational combinations designed to convert immunologically "cold" tumors into responsive disease.

Commercially, payers are demanding real-world evidence, companion diagnostic alignment, and measurable outcomes. As biosimilars increase price competition in biologics such as bevacizumab, innovators are focusing on differentiated efficacy, biomarker-defined labels, patient convenience, and lifecycle strategies.

Cumulative Impact of Artificial Intelligence on Colorectal Cancer Drugs

Artificial intelligence is becoming a cumulative force across colorectal cancer drug discovery, clinical development, diagnostics, and commercialization. In discovery, AI-supported modeling helps prioritize targets, identify drug-like molecules, analyze resistance pathways, and accelerate hypothesis generation from genomics, transcriptomics, pathology images, and real-world clinical datasets.

In clinical trials, AI can improve site selection, patient matching, synthetic control evaluation, and protocol feasibility analysis. This is especially important in colorectal cancer, where biomarker-defined populations such as BRAF V600E, HER2-positive, NTRK fusion-positive, and MSI-H/dMMR subsets are clinically meaningful but may represent smaller patient groups. AI-enabled trial optimization can reduce recruitment friction and support more efficient evidence generation when used with validated data governance and regulatory oversight.

In care delivery, AI-assisted colonoscopy, digital pathology, and radiology tools support earlier detection, treatment stratification, and response assessment. The strongest near-term advantage for drug developers will come from integrating AI with validated companion diagnostics, real-world evidence platforms, pharmacovigilance systems, and market access analytics.

Key Regional Insights Across Global Colorectal Cancer Drug Markets

North America remains a leading region for colorectal cancer drug innovation due to strong oncology research infrastructure, high adoption of molecular diagnostics, broad access to biologics and immunotherapies, and a mature reimbursement environment. The United States drives much of the region's clinical trial activity and launch sequencing, while Canada continues to emphasize evidence-based access through health technology assessment and provincial reimbursement pathways.

Europe benefits from centralized regulatory review, established cancer networks, and increasing use of genomic testing, although access can vary by country because pricing and reimbursement decisions remain nationally managed. Asia-Pacific is expanding as China, Japan, South Korea, Australia, and India invest in oncology infrastructure, local clinical trials, and domestic biopharmaceutical innovation. Japan and South Korea show strong adoption of advanced therapies, while China's regulatory reforms and clinical development capacity have made it an increasingly important development and commercialization market.

Latin America shows growing demand for colorectal cancer drugs, led by Brazil and Mexico, but access gaps persist due to uneven screening coverage, public-sector budget constraints, and variable availability of biomarker testing. The Middle East, particularly GCC countries, is investing in specialized oncology centers and advanced diagnostics. Africa remains the most access-constrained region, with late-stage diagnosis, limited pathology capacity, and affordability barriers shaping demand for essential chemotherapy, biosimilars, and scalable cancer care programs.

Key Group Insights for Colorectal Cancer Drug Commercial Strategy

The G7 countries remain central to colorectal cancer drug innovation, reimbursement policy, and clinical guideline development, supported by large oncology budgets, sophisticated trial networks, and high adoption of targeted therapies. The European Union adds scale through harmonized regulatory pathways and cross-border research initiatives, although access still depends on national health technology assessment, budget impact reviews, and negotiated pricing.

BRICS markets are increasingly influential because of population scale, rising cancer burden, and expanding local pharmaceutical capabilities. China and India are especially important for cost-sensitive access models, biosimilar uptake, and clinical trial recruitment, while Brazil and South Africa highlight the need for equitable public-sector oncology access. Russia maintains oncology demand but faces market complexity related to procurement, localization, and geopolitical constraints.

ASEAN markets are diverse, with Singapore and Thailand offering stronger specialty oncology infrastructure than many lower-income member states. GCC countries are prioritizing advanced cancer centers, medical tourism, and precision oncology adoption under national health modernization programs. NATO members overlap significantly with high-income North American and European systems, where supply chain resilience, medicine security, and collaborative research funding increasingly influence oncology drug availability.

Key Country Insights Shaping Colorectal Cancer Drug Demand

The United States is highly influential in colorectal cancer drug development and adoption, supported by FDA innovation pathways, broad oncology trial activity, and rapid uptake of biomarker-driven regimens, though payer scrutiny of high-cost therapies is intensifying. Canada emphasizes clinical value and public reimbursement evidence, while Mexico's progress depends on strengthening screening, diagnostic access, and specialty oncology capacity. Brazil is a key Latin American market, with demand shaped by public and private system differences and the availability of biosimilars and targeted agents.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine mature oncology systems with rigorous cost-effectiveness evaluation. Germany often enables earlier post-approval access, while the United Kingdom and France apply structured health technology assessment and outcome-based value considerations. Russia remains a sizable oncology treatment environment but is affected by procurement priorities, localization requirements, and geopolitical constraints.

China is becoming a major engine for colorectal cancer drug development, local trials, and domestic oncology innovation. India offers significant long-term demand but remains highly price-sensitive, making generics, biosimilars, and scalable diagnostics essential. Japan has strong uptake of precision oncology and an aging population that sustains treatment demand. South Korea is notable for advanced diagnostics and biopharma innovation, while Australia combines high screening awareness, strong clinical research participation, and evidence-based reimbursement.

Actionable Recommendations for Colorectal Cancer Drug Industry Leaders

Industry leaders should prioritize biomarker-led development strategies that align drug candidates with validated diagnostic pathways and clearly defined patient populations. Expanding evidence in MSI-H/dMMR, BRAF-mutant, HER2-positive, KRAS-mutant, and other molecularly selected colorectal cancer groups can support differentiated positioning and stronger reimbursement narratives.

Organizations should invest in real-world evidence, patient-reported outcomes, and comparative effectiveness data to demonstrate durable clinical value beyond registration trials. Partnerships with diagnostic developers, academic cancer centers, and integrated delivery networks can accelerate patient identification and improve trial enrollment.

Commercial teams should tailor access strategies by region, using premium innovation models in high-income markets and affordability-focused approaches in emerging markets. Biosimilar competition, supply chain resilience, and value-based contracting should be integrated into lifecycle planning from the earliest stages of product strategy.

Research Methodology for Evidence-Based Market Intelligence

This executive summary is developed using a structured secondary research methodology focused on verified public-domain and industry-recognized sources. Inputs include global cancer burden data from WHO and IARC/GLOBOCAN, regulatory information from agencies such as the FDA, EMA, and national authorities, clinical guidance from oncology societies, peer-reviewed literature, health technology assessment outputs, and official public health resources.

The analysis triangulates epidemiology, treatment guidelines, drug approvals, pipeline activity, reimbursement dynamics, and regional access conditions to identify strategic trends in colorectal cancer therapeutics. Market interpretations emphasize evidence-backed directionality rather than unsupported numerical forecasts.

Quality control includes source validation, cross-checking of clinical claims against recognized oncology references, review of regional health system factors, and exclusion of unverified promotional claims. The methodology is designed to support executive decision-making for product strategy, market access, clinical development, and competitive intelligence.

Conclusion: Strategic Outlook for Colorectal Cancer Drugs

The colorectal cancer drugs landscape is entering a more precise, data-driven phase in which molecular testing, immunotherapy, targeted combinations, and real-world evidence increasingly determine clinical and commercial success. While chemotherapy remains foundational, the strongest opportunities are emerging in biomarker-defined populations and therapies that can demonstrate meaningful survival, tolerability, and access advantages.

Regional disparities will continue to shape uptake, with high-income markets leading innovation adoption and emerging markets requiring cost-effective diagnostics, biosimilars, and broader cancer care infrastructure. Organizations that combine scientific differentiation with practical access strategies will be best positioned to serve patients and capture sustainable value.

Across the global colorectal cancer therapeutics landscape, success will depend on evidence quality, diagnostic integration, affordability, and the ability to adapt to rapidly evolving standards of care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Colorectal Cancer Drugs Market, by Drug Class

  • 7.1. Chemotherapy
    • 7.1.1. Fluoropyrimidines
    • 7.1.2. Platinum Compounds
    • 7.1.3. Topoisomerase Inhibitors
  • 7.2. Immunotherapy
    • 7.2.1. Adoptive Cell Therapies
    • 7.2.2. Checkpoint Inhibitors
  • 7.3. Monoclonal Antibodies
    • 7.3.1. Epidermal Growth Factor Receptor Inhibitors
    • 7.3.2. Vascular Endothelial Growth Factor Inhibitors
  • 7.4. Small Molecule Inhibitors
    • 7.4.1. BRAF Inhibitors
    • 7.4.2. MEK Inhibitors
    • 7.4.3. Tyrosine Kinase Inhibitors

8. Colorectal Cancer Drugs Market, by Route Of Administration

  • 8.1. Intravenous
  • 8.2. Oral
  • 8.3. Subcutaneous

9. Colorectal Cancer Drugs Market, by Line Of Therapy

  • 9.1. First Line
  • 9.2. Second Line
  • 9.3. Third Line

10. Colorectal Cancer Drugs Market, by Target Molecule

  • 10.1. Epidermal Growth Factor Receptor
  • 10.2. Programmed Cell Death Protein 1
  • 10.3. Programmed Death Ligand 1
  • 10.4. Vascular Endothelial Growth Factor

11. Colorectal Cancer Drugs Market, by Treatment Setting

  • 11.1. Inpatient
  • 11.2. Outpatient

12. Colorectal Cancer Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Colorectal Cancer Drugs Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Colorectal Cancer Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Colorectal Cancer Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Accord Healthcare Limited by Intas Pharmaceuticals Ltd.
  • 17.3. Amgen Inc.
  • 17.4. Amneal Pharmaceuticals, Inc.
  • 17.5. Apotex Inc.
  • 17.6. AstraZeneca PLC
  • 17.7. Bayer AG
  • 17.8. Bristol-Myers Squibb Company
  • 17.9. Eisai Co., Ltd.
  • 17.10. Eli Lilly and Company
  • 17.11. Exelixis, Inc.
  • 17.12. F. Hoffmann-La Roche Ltd
  • 17.13. GlaxoSmithKline PLC
  • 17.14. HUTCHMED (China) Limited
  • 17.15. Johnson & Johnson
  • 17.16. Lupin Limited
  • 17.17. Mallinckrodt Pharmaceuticals
  • 17.18. Manus Aktteva Biopharma LLP
  • 17.19. Marksans Pharma Ltd.
  • 17.20. Merck & Co., Inc.
  • 17.21. Mylan N.V. by Viatris Inc.
  • 17.22. Novartis AG
  • 17.23. Pfizer Inc.
  • 17.24. Regeneron Pharmaceuticals, Inc.
  • 17.25. Sanofi S.A.
  • 17.26. Servier Laboratories
  • 17.27. Sumitomo Pharma Co., Ltd.
  • 17.28. Taiho Pharmaceutical Co., Ltd. by Otsuka Pharmaceutical Co., Ltd.
  • 17.29. Takeda Pharmaceutical Company Limited
  • 17.30. VolitionRx Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL COLORECTAL CANCER DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL COLORECTAL CANCER DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL COLORECTAL CANCER DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL COLORECTAL CANCER DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL COLORECTAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL COLORECTAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FLUOROPYRIMIDINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FLUOROPYRIMIDINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FLUOROPYRIMIDINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PLATINUM COMPOUNDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PLATINUM COMPOUNDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PLATINUM COMPOUNDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TOPOISOMERASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TOPOISOMERASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TOPOISOMERASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ADOPTIVE CELL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ADOPTIVE CELL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ADOPTIVE CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SMALL MOLECULE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SMALL MOLECULE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SMALL MOLECULE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRAF INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAF INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MEK INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MEK INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MEK INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FIRST LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FIRST LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FIRST LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SECOND LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SECOND LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SECOND LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL THIRD LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL THIRD LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL THIRD LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL EPIDERMAL GROWTH FACTOR RECEPTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL EPIDERMAL GROWTH FACTOR RECEPTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL EPIDERMAL GROWTH FACTOR RECEPTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PROGRAMMED CELL DEATH PROTEIN 1 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PROGRAMMED CELL DEATH PROTEIN 1 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PROGRAMMED CELL DEATH PROTEIN 1 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PROGRAMMED DEATH LIGAND 1 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PROGRAMMED DEATH LIGAND 1 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PROGRAMMED DEATH LIGAND 1 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VASCULAR ENDOTHELIAL GROWTH FACTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VASCULAR ENDOTHELIAL GROWTH FACTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VASCULAR ENDOTHELIAL GROWTH FACTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INPATIENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INPATIENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INPATIENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OUTPATIENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OUTPATIENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OUTPATIENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. GCC COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 179. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 180. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 184. GCC COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. G7 COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 209. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 212. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 213. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 217. G7 COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. NATO COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 220. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 222. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 223. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 224. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 227. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 228. NATO COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL COLORECTAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 243. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 246. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 247. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 250. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 251. CANADA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 254. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 255. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 257. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 258. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 260. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 261. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 262. MEXICO COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 265. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 267. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 268. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 269. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 271. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 272. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 273. BRAZIL COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED KINGDOM COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 287. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 288. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 289. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 290. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 291. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 292. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 293. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 294. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 295. GERMANY COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 296. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 298. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 299. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 300. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 301. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 302. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 303. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 304. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 305. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 306. FRANCE COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 307. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 308. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 309. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 310. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 311. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 312. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 313. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 314. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 315. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 316. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 317. RUSSIA COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 318. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 319. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 320. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 321. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 322. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 323. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 324. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 325. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 326. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 327. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 328. ITALY COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 329. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 330. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 331. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 332. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 333. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 334. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 335. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 336. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 337. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 338. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 339. SPAIN COLORECTAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 34